Sir, We note with interest that Livermore and colleagues have not detected any Staphylococcus aureus isolates with reduced susceptibility to vancomycin despite screening approximately 26 000 strains. 1 Since April 2000, in our department, all isolates of S. aureus have been screened for reduced susceptibility to vancomycin. 2, 3 As of February 2001 3713 isolates, 39% of which were methicillin resistant, had been examined. Sixty-six per cent of the methicillinresistant S. aureus (MRSA) isolates were EMRSA groups 15 or 16. An agar incorporation method with brain-heart infusion agar (Oxoid, Basingstoke, UK) and multipoint inoculation of 10 6 cfu/spot was used, as recommended.
3
Enterococcus faecalis NCTC 12697 (vancomycin MIC 4 mg/L) was included as a control. Plates were incubated at 37°C and examined at 24 h. A series of plates (0, 2, 4, 6 and 8 mg/L vancomycin) was chosen in preference to a single breakpoint plate method for several reasons: vancomycin MICs for strains displaying reduced susceptibility to glycopeptides are only two-to eight-fold above the values typical for susceptible S. aureus; 2,3 using more than one breakpoint plate reduced the likelihood of recording inaccurate results arising from variations in media prepared in-house; uncertainty of the distribution of vancomycin MICs for our S. aureus clinical isolates; and current breakpoint testing recommendations are based on isolates obtained from non-UK populations. 3 Only six of 3713 isolates (0.16%) yielded three or more colonies on plates containing 4 mg/L vancomycin. All of these were confirmed as fully susceptible to vancomycin by Etest on Iso-Sensitest agar; four and two strains had vancomycin MICs of 2 and 1.5 mg/L, respectively. Isolates of S. aureus with vancomycin MICs of 4 mg/L were not uncommon (15.9%), and we agree with Livermore and colleagues that there is little value in considering such isolates of major significance, as American workers have suggested. 4 Our findings confirm that the current prevalence of S. aureus strains with reduced susceptibility to vancomycin, in the setting of a tertiary referral hospital, is extremely low. This is not an excuse for complacency, but rather a definitive baseline against which future surveillance results can be compared.
